| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CONTINUING EDUCATION |
Nuclear Medicine Service, Department of Internal Medicine and Medical Specialties, University of Genoa Medical School, Genoa; Division of Surgical Oncology, Department of Oncology, Biology and Genetics, University of Genoa and National Cancer Institute, Genoa; Division of Surgical Oncology, National Cancer Institute, Genoa; Department of Pathology and Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy; Department of Nuclear Medicine, Royal Free Hospital and School of Medicine, London, United Kingdom; and Division of Nuclear Medicine, Department of Radiology, Stanford University School of Medicine, Stanford, California
The concept of sentinel lymph node biopsy in breast cancer surgery relates to the fact that the tumor drains in a logical way through the lymphatic system, from the first to upper levels. Therefore, the first lymph node met (the sentinel node) will most likely be the first to be affected by metastasis, and a negative sentinel node makes it highly unlikely that other nodes are affected. Because axillary node dissection does not improve prognosis of patients with breast cancer (being important only to stage the axilla), sentinel lymph node biopsy might replace complete axillary dissection to stage the axilla in clinically N0 patients. Sentinel lymph node biopsy would represent a significant advantage as a minimally invasive procedure, considering that, after surgery, about 70% of patients are found to be free from metastatic disease, yet axillary node dissection can lead to significant morbidity. Furthermore, histologic sampling errors can be reduced if a single (sentinel) node is assessed extensively rather than few histologic sections in a high number of lymph nodes per patient. Although the pattern of lymph drainage from breast cancer can be variable, the mammary gland and the overlying skin can be considered as a biologic unit in which lymphatics tend to follow the vasculature. Therefore, considering that tumor lymphatics are disorganized and relatively ineffective, subdermal and peritumoral injection of small aliquots of radiotracer is preferred to intratumoral administration. 99mTc-labeled colloids with most of the particles in the 100- to 200-nm size range would be ideal for radioguided sentinel node biopsy in breast cancer. Lymphoscintigraphy is an essential part of radioguided sentinel lymph node biopsy because images are used to direct the surgeon to the site of the node. The sentinel lymph node should have a significantly higher count than that of background (at least 10:1 intraoperatively). After removal of the sentinel node, the axilla must be reexamined to ensure that all radioactive sites are identified and removed for analysis. The sentinel lymph node should be processed for intraoperative frozen section examination in its entirety, based on conventional histopathology and, when needed, immune staining with anticytokeratin antibody. The success rate of radioguidance in localizing the sentinel lymph node in breast cancer surgery is about 94%–97% in institutions where a high number of procedures are performed and approaches 99% when combined with the vital blue dye technique. At present, there is no definite evidence that negative sentinel lymph node biopsy is invariably correlated with negative axillary status, except perhaps for T1a-b breast cancers, with a size of 
1 cm. Randomized clinical trials should elucidate the impact of avoiding axillary node dissection on patients with a negative sentinel lymph node on the long-term clinical outcome of patients.
Key Words: sentinel lymph node • breast cancer • radiocolloid • interstitial administration • lymphoscintigraphy • intraoperative 
-probe guidance
This article has been cited by other articles:
|
|
 |
|
  A.-S. Bats, V. Lavoue, R. Rouzier, C. Coutant, K. Kerrou, and E. Darai Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer Ann. Surg. Oncol., August 1, 2008; 15(8): 2173 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tsuchimochi, K. Hayama, T. Oda, M. Togashi, and H. Sakahara Evaluation of the Efficacy of a Small CdTe {gamma}-Camera for Sentinel Lymph Node Biopsy J. Nucl. Med., June 1, 2008; 49(6): 956 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. MINIGH Sentinel Lymph Node Mapping of the Breast Radiol. Technol., January 1, 2008; 79(3): 243M - 257M. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jeziorski, J. Piekarski, D. Nejc, P. Pluta, P. Sek, A. Bilski, A. Durczynski, and K. Wronski Ex vivo Search for Sentinel Node in Postmastectomy Specimens: Should We Use a Transverse Incision for Mastectomy? Ann. Surg. Oncol., November 1, 2007; 14(11): 3111 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tanaka, H. S. Choi, H. Fujii, M. G. Bawendi, and J. V. Frangioni Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node Mapping Ann. Surg. Oncol., December 1, 2006; 13(12): 1671 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsushima, T. Takayama, T. Yamanaga, H. Kizu, Y. Shimonishi, K. Kosakai, A. Noguchi, and M. Onoguchi Usefulness of Medium-Energy Collimator for Sentinel Node Lymphoscintigraphy Imaging in Breast Cancer Patients. J. Nucl. Med. Technol., September 1, 2006; 34(3): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rousseau, J. M. Classe, L. Campion, C. Curtet, F. Dravet, R. Pioud, C. Sagan, B. Bridji, and I. Resche The Impact of Nonvisualization of Sentinel Nodes on Lymphoscintigraphy in Breast Cancer Ann. Surg. Oncol., July 1, 2005; 12(7): 533 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Paganelli, M. Cremonesi, M. Ferrari, G. Trifiro, O. Gentilini, and A. Luini Reply to the Letter to the Editor on Safety of sentinel node biopsy in pregnant patients, by G. Dubernard et al. (Ann Oncol 2005; 16: 987) Ann. Onc., June 1, 2005; 16(6): 987 - 988. [Full Text] [PDF]
|
|
|
|
|
|
G. Mariani, A. Vaiano, O. Nibale, and D. Rubello Is the "Ideal" {gamma}-Probe for Intraoperative Radioguided Surgery Conceivable? J. Nucl. Med., March 1, 2005; 46(3): 388 - 390. [Full Text] [PDF]
|
|
|
|
|
|
O. Gentilini, M. Cremonesi, G. Trifiro, M. Ferrari, S. M. Baio, M. Caracciolo, A. Rossi, A. Smeets, V. Galimberti, A. Luini, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer Ann. Onc., September 1, 2004; 15(9): 1348 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ueda, K. Suga, Y. Kaneda, H. Sakano, T. Tanaka, M. Hayashi, T.-S. Li, and K. Hamano Radioisotope lymph node mapping in nonsmall cell lung cancer: can it be applicable for sentinel node biopsy? Ann. Thorac. Surg., February 1, 2004; 77(2): 426 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pelosi, M. Bello, M. Giors, A. Ala, R. Giani, R. Bussone, and G. Bisi Sentinel Lymph Node Detection in Patients with Early-Stage Breast Cancer: Comparison of Periareolar and Subdermal/Peritumoral Injection Techniques J. Nucl. Med., February 1, 2004; 45(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suga, Y. Yuan, M. Okada, N. Matsunaga, A. Tangoku, S. Yamamoto, and M. Oka Breast Sentinel Lymph Node Mapping at CT Lymphography with Iopamidol: Preliminary Experience Radiology, February 1, 2004; 230(2): 543 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Krynyckyi, C. K. Kim, M. R. Goyenechea, P. T. Chan, Z.-Y. Zhang, and J. Machac Clinical Breast Lymphoscintigraphy: Optimal Techniques for Performing Studies, Image Atlas, and Analysis of Images RadioGraphics, January 1, 2004; 24(1): 121 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Law, K C Cheng, P M Wu, W Y Ho, and L W C Chow Patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a study using a female humanoid phantom and thermoluminescent dosemeters Br. J. Radiol., November 1, 2003; 76(911): 818 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Krynyckyi, H. Chun, H. H. Kim, Y. Eskandar, C. K. Kim, and J. Machac Factors Affecting Visualization Rates of Internal Mammary Sentinel Nodes During Lymphoscintigraphy J. Nucl. Med., September 1, 2003; 44(9): 1387 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Even-Sapir, H. Lerman, G. Lievshitz, A. Khafif, D. M. Fliss, A. Schwartz, E. Gur, Y. Skornick, and S. Schneebaum Lymphoscintigraphy for Sentinel Node Mapping Using a Hybrid SPECT/CT System J. Nucl. Med., September 1, 2003; 44(9): 1413 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wallace, C. K. Hoh, D. R. Vera, D. D. Darrah, and G. Schulteis Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection Ann. Surg. Oncol., June 1, 2003; 10(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koizumi, M. Makita, M. Yoshimoto, F. Kasumi, G. Sakamoto, and E. Ogata Indications for Sentinel Lymph Node Biopsy in Patients with Breast Cancer: Retrospective and Simulation Analyses Jpn. J. Clin. Oncol., December 1, 2002; 32(12): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bonnema and C. J. H. van de Velde Sentinel lymph node biopsy in breast cancer Ann. Onc., October 1, 2002; 13(10): 1531 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al. Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma* J. Nucl. Med., June 1, 2002; 43(6): 811 - 827. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
